South America Ovarian Cancer Diagnostics and Therapeutics Market to Reflect Impressive Growth Rate of 10.5% by 2023 | Key Players - Bristol Myers Squibb Company, Eli Lilly and Company, Janssen Pharmaceuticals, Genentech, Astra Zeneca Boehringer Ingelheim

South America Ovarian Cancer Diagnostics and Therapeutics Market Highlights
The South American ovarian cancer diagnostics and therapeutics market is expected to register a CAGR of 10.5% during the forecast period, 2018 to 2023. Brazil is expected to dominate the market for ovarian cancer diagnostics and therapeutics due to the increasing incidence of ovarian cancer.

Get your sample report now @ https://marketprognosis.com/sample-request/17095
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Incidence of Ovarian Cancer
The risk of ovarian cancer increases in women in the age bracket of 55-64 years. The annual mortality rate per 100,000 people from ovarian cancer in South America has increased 117.6% since 1990, an average of 5.1% a year. Thus, due to the increasing incidence of ovarian cancer in South America, the diagnostics and therapeutics market is also growing in the region.
Additionally, greater use of combination therapies for the treatment of ovarian cancer, increase in the population of aged women, and increase in healthcare expenditure in developing countries are fueling the growth of the South American ovarian cancer diagnostics and therapeutics market.

Key Developments in the Market
May 2017 - A new drug developed for ovarian cancer ONX-0801 is in Phase1.

The major players include –
Bristol Myers Squibb Company, Eli Lilly and Company, GlaxosmithklinePlc, Janssen Pharmaceuticals, Inc., Genentech Inc., Astra Zeneca Boehringer Ingelheim, and F. Hoffman-La Roche Ltd, among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/17095
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Lack of Accurate Diagnosis of Ovarian Cancer
Accurate diagnosis for ovarian cancer is critical, as in most cases, the cancer already begins to spread to the lymph nodes and outside of the pelvis at the time of diagnosis. Ovariancancerawareness.org reports that the five-year survival rate for ovarian cancer with early stage 1 detection is 93% and that most new cases of ovarian cancer are diagnosed at stage 3 or later, leaving little time as well as room for an accurate diagnosis. Lack of early detection and accurate diagnosis is often since ovarian cancer symptoms are frequently overlooked, and easily confused with other conditions. Additionally, patent expiry of key drugs is also restraining the growth of the ovarian cancer diagnostics and therapeutics market.

Brazil to Dominate the Market
Ovarian cancer (OC) is the eighth most common cancer among women in Brazil. OC has a high mortality rate and is difficult to diagnose. Due to its silent progression, it is contributing to the high mortality rate. Thus, due to the increasing incidence of ovarian cancer, the market for cancer diagnostics and therapeutics is expected to see a stable growth in South America.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/17095
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.